Crossmark

Menopausal hormone therapy—ovarian cancer risk revisited

Crossref DOI link: https://doi.org/10.1038/nrendo.2015.33

Published Online: 2015-03-10

Published Print: 2015-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Davis, Susan R.

Baber, Rodney
License Information

Text and Data Mining valid from 2015-03-10
More Information

Article History

First Online: 10 March 2015

Competing interests

: S.R.D. declares that she has received an honorarium from Abbott, is a consultant for Trimel Pharmaceuticals and has received research support from Lawley Pharmaceuticals. R.B. declares that he has received honoraria from Abbott and Bayer for providing continuing education lectures.